Hims and Ro have both moved to selling branded GLP-1 subscriptions and the membership fee around them buys the drug and little else. GoodLife Health sells the clinical relationship, includes four lab panels a year and earns nothing on the medication, which is a different business with different incentives. Is this just Hims, Ro or MEDVi with a higher price? No and the difference is not the price tag. It is what the company is allowed to care about.
- GoodLife Health's $299-a-month membership covers the clinician and quarterly labs, never the medication.
- Medication is billed separately by your pharmacy at its own price, with zero markup from GoodLife Health.
- Branded subscription apps now sell branded GLP-1 bundles commonly reported around $499 a month and the fee rises with the dose.
- Compounded-vial platforms like Mochi Health charge roughly a $79-a-month membership plus about $99 to $199 a month for the compounded drug.
- The quarterly Biomarker Audit covers Hs-CRP, Comprehensive Metabolic Panel, TSH With Reflex To Free T4, Fasting Insulin, Lipoprotein (A), Hemoglobin A1c (HbA1c), Lipid Panel, Standard, Apolipoprotein B (ApoB) and more.
- Year-one cost runs about $5,988 for a branded subscription versus $3,588 for the GoodLife Health membership, plus whatever your pharmacy charges for the medicine.
What those platforms actually sell now
It is worth updating the picture, because the market moved. Hims partnered with Novo Nordisk in January 2026 and now sells branded Wegovy on subscription, commonly reported around $499 a month on its own pricing page. It stopped advertising compounded semaglutide but still offers it in limited cases. Ro also pivoted to branded Wegovy and Zepbound and discontinued its compounded program. MEDVi and the other compounded-vial platforms continue to sell compounded GLP-1 through a monthly membership. Mochi Health, the cleanest example of the compounded model still standing, commonly reports a membership of about $79 a month with compounded semaglutide or tirzepatide running roughly $99 to $199 a month on top.
Those are the models, hedged and dated October 2026, because their prices change and ours should be judged on structure rather than on a snapshot. In every one of them the monthly payment is mainly the medication or the medication plus a thin clinical wrapper. The company's revenue rises when the dose rises and when the prescription continues.
What is actually different about the GoodLife Health model
The membership is $299 a month and covers the clinician and the labs. It never covers the medication, because medication is billed separately by the pharmacy you choose at that pharmacy's own price. GoodLife Health sets nothing on the medicine, sees nothing of the transaction and takes nothing from it. You pay one flat fee for the doctor. The medicine carries zero markup.
GoodLife Health vs. the subscription and compounded models
| What you are buying | The $99 to $499 subscription apps | The compounded platforms | GoodLife Health |
|---|---|---|---|
| The clinical relationship | A short telehealth visit, often once | A short telehealth visit | A named clinician, messaging and video visits, for as long as you are a member |
| Labs | Rarely included, often sold as add-ons | Rarely included | A comprehensive Biomarker Audit every 90 days, included |
| The medication | Branded, inside the bundle price | Compounded vials | Branded and FDA-approved only, billed by your pharmacy at its price |
| Who profits if your dose climbs | The platform | The platform | Nobody here. The fee is $299 whatever the dose |
The last row is the whole argument. A platform that earns margin on the molecule has a quiet reason to keep you on it. We removed the reason. When your labs support the lowest effective dose, the protocol aims there, because our revenue is the membership and the membership renews only if your results do.
What the fee buys that a subscription does not
The quarterly Biomarker Audit covers Hs-CRP, Comprehensive Metabolic Panel, TSH With Reflex To Free T4, Fasting Insulin, Lipoprotein (A), Hemoglobin A1c (HbA1c), Lipid Panel, Standard, Apolipoprotein B (ApoB) and more. It is the difference between being prescribed something and being understood.
A subscription that ships the pen without reading your thyroid or your insulin markers cannot tell you why the weight stopped moving, whether a plateau is the dose or a thyroid that is in range but not right or what happens when you reach your goal.
The evidence behind the medication is the same on both sides of the comparison, because the molecules are the same. In STEP 1, adults with overweight or obesity taking semaglutide 2.4 mg lost about 15% of body weight on average over 68 weeks. In SURMOUNT-1, tirzepatide produced average losses of up to about 21% over 72 weeks. Those are trial averages under supervision. Individual results vary and no honest clinic promises a number. The question a subscription cannot answer is what your body will do and why and that answer starts with your biomarkers.
Where the subscription is genuinely the better deal
We would rather name this than pretend otherwise. If you have a clinician you trust who already orders your labs or if your only goal is the lowest possible monthly cost and you accept the thin follow-up, a branded subscription is a reasonable purchase and may cost less in the short run. If you want a compounded vial, we do not prescribe one under any circumstance, so we are not the right home for that. And if you want a guaranteed amount of weight loss, no honest provider on either side of this comparison can offer it.
What you are paying the difference for is the part of medicine that does not show up in a subscription line item. You get a clinician who reads your quarterly panel and rewrites the protocol. You get a message answered by someone who knows your history. You get a prescription written to the pharmacy you choose. You get a fee that never rises with the dose. Whether that is worth $299 a month is a question only your own situation answers and the honest comparison is against what you pay today for the pieces a subscription leaves out.
The year-one math, on both sides
Ground truth for any comparison is both totals with their dates. A branded subscription at around $499 a month runs about $5,988 a year, at the price its own site published in recent months. Our membership is $3,588 for the year, which is the $598 held on your card at sign-up (charged only once a clinician accepts you and released if they cannot) covering two months plus ten further months at $299. Medication is then whatever your pharmacy charges. At the manufacturers' own self-pay prices as of September 2026, Wegovy pens run $199 a month for the first two fills under an introductory offer through December 2026 and $349 a month after, with Zepbound vials $299 to $449 a month depending on dose through LillyDirect.
Add the two charges yourself. The point of publishing the arithmetic is that you can. What the subscription total hides is that labs and follow-up are usually extra or absent and what our total hides is nothing, because the fee and the pharmacy bill are the only two numbers.
Who each model is actually for
The subscription suits the person who wants the drug, has straightforward labs and no complicating picture and is comfortable being managed by a questionnaire. We do not prescribe compounded GLP-1. The FDA's position on compounded copies and the manufacturers' litigation are the backdrop and a clinician's licence carries the responsibility either way. The membership suits the person who has been prescribed things before and never understood, who wants the diagnosis first and the prescription second and who would rather pay one flat fee for the doctor and the pharmacy's own price for the medicine.
If that second description is you, the eligibility check takes about two minutes and the $598 is only held, charged once a clinician accepts you and released if they cannot. Our guide to the true monthly cost of GLP-1 telehealth works through the full all-in comparison, including where the other models are genuinely cheaper.
FAQ
Is GoodLife Health the same as Hims or Ro with a higher price?
No. The subscription apps sell medication in a bundle. Our $299 a month buys the clinical relationship and a Biomarker Audit every 90 days and medication is billed separately by your pharmacy at its own price.
Do you sell compounded semaglutide like MEDVi?
No. We prescribe branded and FDA-approved GLP-1 medication only and never prescribe compounded GLP-1 under any circumstance.
Why does the membership cost more than a $99 app?
The $99 app buys the drug and a short visit. The membership buys a named clinician, four lab panels a year, messaging and video visits and a protocol rewritten as your numbers move.
Does the fee change if my dose goes up?
No. The fee is $299 a month whatever medication is indicated and whatever the dose, with no molecule upcharge and no dose upcharge.
How much does branded Wegovy cost through GoodLife Health?
Whatever your pharmacy charges, because we add nothing. Through NovoCare, Wegovy pens were listed in September 2026 at $199 a month for the first two fills and $349 a month after.
Is the higher fee worth it?
Only you can answer that and the honest test is whether the diagnosis and the follow-through are worth $299 a month to you. The trial evidence is the same either way and the difference is whether anyone is reading your labs.
One last thing
The subscription model asks whether you can afford the drug. The membership asks what the drug is supposed to be fixing.
If you have ever stopped a GLP-1 and watched the weight return while nobody checked the insulin resistance or the thyroid underneath it, you already know which question was left unanswered.
Related Guides
- Branded GLP-1 medications at pass-through prices
- The true monthly cost of GLP-1 telehealth
- Medical weight loss at GoodLife Health
Sources: STEP 1, semaglutide 2.4 mg in adults with overweight or obesity and SURMOUNT-1, tirzepatide for obesity. Competitor and manufacturer prices as published, hedged, October 2026.
References
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). 2021. pubmed.ncbi.nlm.nih.gov/33567185/
- Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). 2022. pubmed.ncbi.nlm.nih.gov/35658024/